The FDA issued a warning letter to Hospira citing concerns regarding contamination of drugs produced at its facility in Tamil Nadu, India. The FDA discovered major quality breaches for finished medicines during an inspection in October. Sterile drug products were unprotected from contamination and the facility's surfaces weren't always sanitized before use, the FDA said. The agency is also taking a closer look at Indian drugmakers after manufacturing issues were raised against generics-makers Wockhardt and Ranbaxy Laboratories.
Published in Brief: